on PREDILIFE (EPA:ALPRE)
PREDILIFE: 2024 Results and 2025 Outlook
PREDILIFE, a specialist in artificial intelligence for personalized medicine, has announced encouraging results for 2024. The company sold 2,200 predictive assessments, a 120% increase over the previous year, resulting in revenue of €493,000, up 55% from 2023. This momentum is accentuated by deferred income, which increased by 174% to €449,000.
The MammoRisk breast cancer screening program reached a significant milestone with the completion of the MyPeBS study, which enrolled 53,000 women. MammoRisk's potential value has been estimated at €207 million, representing significant growth potential in the European market.
PREDILIFE anticipates a doubling of sales by 2025. The company is also exploring strategic partnerships for MammoRisk, considering alliances with pharmaceutical companies, investment funds, or an IPO in either Europe or the United States.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PREDILIFE news